126 related articles for article (PubMed ID: 38700323)
21. Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System.
Liu Y; Dong C; He X; Shu Y; Wu P; Zou J
J Pharm Pharm Sci; 2022; 25():377-390. PubMed ID: 36608646
[TBL] [Abstract][Full Text] [Related]
22. Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system.
Jiang T; Su H; Li Y; Wu Y; Ming Y; Li C; Fu R; Feng L; Li Z; Li L; Ni R; Liu Y
Front Pharmacol; 2022; 13():989032. PubMed ID: 36532784
[No Abstract] [Full Text] [Related]
23. Liver injury due to endothelin receptor antagonists: a real-world study based on post-marketing drug monitoring data.
Dong S; Guo X; Wang H; Sun C
Ther Adv Respir Dis; 2024; 18():17534666231223606. PubMed ID: 38179676
[TBL] [Abstract][Full Text] [Related]
24. Analysis of Inclisiran in the US FDA Adverse Event Reporting System (FAERS): a focus on overall patient population and sex-specific subgroups.
He Y; Guan X; Zhang Y; Zhu Z; Zhang Y; Feng Y; Li X
Expert Opin Drug Saf; 2024 May; ():1-9. PubMed ID: 38676389
[TBL] [Abstract][Full Text] [Related]
25. A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
Cui Z; Cheng F; Wang L; Zou F; Pan R; Tian Y; Zhang X; She J; Zhang Y; Yang X
Front Pharmacol; 2023; 14():1259908. PubMed ID: 37954852
[No Abstract] [Full Text] [Related]
26. Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database.
Zou F; Cui Z; Lou S; Ou Y; Zhu C; Shu C; Chen J; Zhao R; Wu Z; Wang L; Chen Z; Chen H; Lan Y
Front Pharmacol; 2024; 15():1338902. PubMed ID: 38434706
[No Abstract] [Full Text] [Related]
27. Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database.
Jiang Y; Cheng Y; Du Z; Shen Y; Zhou Q; Ji Y; Zhu H
J Psychopharmacol; 2024 Jun; 38(6):567-578. PubMed ID: 38678377
[TBL] [Abstract][Full Text] [Related]
28. Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database.
Zhao D; Zhang W; Liu Y; Yan Z
Front Pharmacol; 2024; 15():1389814. PubMed ID: 38783948
[TBL] [Abstract][Full Text] [Related]
29. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
[TBL] [Abstract][Full Text] [Related]
30. Signal detection of adverse reactions for bendamustine based on FDA adverse event reporting system.
Huang Q; Wu Y; Li H
Expert Opin Drug Saf; 2024 Apr; ():1-11. PubMed ID: 38682580
[TBL] [Abstract][Full Text] [Related]
31. Potential adverse events associated with sphingosine-1-phosphate (S1P) receptor modulators in patients with multiple sclerosis: an analysis of the FDA adverse event reporting system (FAERS) database.
Yang X; Yan Y; Liu S; Wang Z; Feng X
Front Pharmacol; 2024; 15():1376494. PubMed ID: 38846098
[TBL] [Abstract][Full Text] [Related]
32. Post-marketing safety concerns of sotorasib: A disproportionality analysis based on FDA adverse event reporting system.
Ding Y; Su H; Shu Y; Chen J
Heliyon; 2024 May; 10(9):e30437. PubMed ID: 38726179
[TBL] [Abstract][Full Text] [Related]
33. Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System.
Zhao D; Long X; Zhou J; Wang J
Drugs R D; 2023 Dec; 23(4):403-409. PubMed ID: 37700091
[TBL] [Abstract][Full Text] [Related]
34. A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil.
Wang Y; Zhao B; Yang H; Wan Z
Andrology; 2024 May; 12(4):785-792. PubMed ID: 37724699
[TBL] [Abstract][Full Text] [Related]
35. Safety of daratumumab in the real-world: a pharmacovigilance study based on FAERS database.
Wu J; Wu H; Chen L; Liang H; Huang G; Yang S; Chen B; Noguchi Y; Shen Y
Expert Opin Drug Saf; 2023 Dec; ():1-12. PubMed ID: 38108285
[TBL] [Abstract][Full Text] [Related]
36. Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system.
Sun W; Li Y; Xia B; Chen J; Liu Y; Pang J; Liu F; Cheng H
Front Pharmacol; 2023; 14():1257282. PubMed ID: 38264523
[No Abstract] [Full Text] [Related]
37. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
[TBL] [Abstract][Full Text] [Related]
38. Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system.
Xiong R; Lei J; Pan S; Zhang H; Tong Y; Wu W; Huang Y; Lai X
Front Pharmacol; 2023; 14():1226086. PubMed ID: 37781705
[No Abstract] [Full Text] [Related]
39. Discovering clinical drug-drug interactions with known pharmacokinetics mechanisms using spontaneous reporting systems and electronic health records.
Jeong E; Su Y; Li L; Chen Y
J Biomed Inform; 2024 May; 153():104639. PubMed ID: 38583580
[TBL] [Abstract][Full Text] [Related]
40. A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor.
Pan Y; Wang Y; Zheng Y; Chen J; Li J
Front Pharmacol; 2024; 15():1251961. PubMed ID: 38655177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
